Neal JW. Flaviviruses are neurotropic, but how do they invade the CNS? J Infect. 2014;69(3):203–15.
Domingues RB, et al. Involvement of the central nervous system in patients with dengue virus infection. J Neurol Sci. 2008;267(1–2):36–40.
Puerta-Guardo H, et al. Flavivirus NS1 triggers tissue-specific vascular endothelial dysfunction reflecting disease tropism. Cell Rep. 2019;26(6):1598–613.
Chao CH, et al. Dengue virus nonstructural protein 1 activates platelets via Toll-like receptor 4, leading to thrombocytopenia and hemorrhage. PLoS Pathog. 2019;15(4):e1007625.
Guzman MG, et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8(12 Suppl):S7-16.
Vasilakis N, et al. Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health. Nat Rev Microbiol. 2011;9(7):532–41.
Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine. 2012;30(29):4301–6.
Perera-Lecoin M, et al. Flavivirus entry receptors: an update. Viruses. 2013;6(1):69–88.
Meertens L, et al. Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses. Cell Rep. 2017;18(2):324–33.
Richard AS, et al. AXL-dependent infection of human fetal endothelial cells distinguishes Zika virus from other pathogenic flaviviruses. Proc Natl Acad Sci USA. 2017;114(8):2024–9.
Yun SI, Lee YM. Early events in Japanese encephalitis virus infection: viral entry. Pathogens. 2018;7(3):68.
Apte-Sengupta S, Sirohi D, Kuhn RJ. Coupling of replication and assembly in flaviviruses. Curr Opin Virol. 2014;9:134–42.
Lindenbach BD. Virion assembly and release. Curr Top Microbiol Immunol. 2013;369:199–218.
Zhang Y, et al. Conformational changes of the flavivirus E glycoprotein. Structure. 2004;12(9):1607–18.
Stettler K, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823–6.
Zhang S, et al. Role of BC loop residues in structure, function and antigenicity of the West Nile virus envelope protein receptor-binding domain III. Virology. 2010;403(1):85–91.
Huerta V, et al. Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. Virus Res. 2008;137(2):225–34.
Gallichotte EN, et al. CD-loop extension in Zika virus envelope protein key for stability and pathogenesis. J Infect Dis. 2017;216(10):1196–204.
Tsai WY, et al. C-terminal helical domains of dengue virus type 4 E protein affect the expression/stability of prM protein and conformation of prM and E proteins. PLoS One. 2012;7(12):e52600.
Dai L, et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe. 2016;19(5):696–704.
Luca VC, et al. Crystal structure of the Japanese encephalitis virus envelope protein. J Virol. 2012;86(4):2337–46.
Despres P, et al. The 15 amino acid residues preceding the amino terminus of the envelope protein in the yellow fever virus polyprotein precursor act as a signal peptide. Virus Res. 1990;16(1):59–75.
Hsieh SC, Tsai WY, Wang WK. The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum. J Virol. 2010;84(9):4782–97.
Purdy DE, Chang GJ. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. Virology. 2005;333(2):239–50.
Johnson AJ, Guirakhoo F, Roehrig JT. The envelope glycoproteins of dengue 1 and dengue 2 viruses grown in mosquito cells differ in their utilization of potential glycosylation sites. Virology. 1994;203(2):241–9.
Monath TP, et al. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002;76(4):1932–43.
Goo L, et al. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions. Nat Microbiol. 2019;4(1):71–7.
Annamalai AS, et al. Zika virus encoding nonglycosylated envelope protein is attenuated and defective in neuroinvasion. J Virol. 2017. https://doi.org/10.1128/JVI.01348-17.
Goto A, et al. A BHK-21 cell culture-adapted tick-borne encephalitis virus mutant is attenuated for neuroinvasiveness. Vaccine. 2003;21(25–26):4043–51.
Konishi E, Mason PW. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J Virol. 1993;67(3):1672–5.
Lorenz IC, et al. Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J Virol. 2002;76(11):5480–91.
Gallichotte EN, et al. Role of Zika virus envelope protein domain III as a target of human neutralizing antibodies. mBio. 2019. https://doi.org/10.1128/mBio.01485-19.
Mary JA, et al. A synthetic peptide derived from domain III envelope glycoprotein of Dengue virus induces neutralizing antibody. Virus Genes. 2018;54(1):25–32.
Bai F, et al. Antiviral peptides targeting the west nile virus envelope protein. J Virol. 2007;81(4):2047–55.
Kuhn RJ, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002;108(5):717–25.
Rodenhuis-Zybert IA, Wilschut J, Smit JM. Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci. 2010;67(16):2773–86.
Chen Y, et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med. 1997;3(8):866–71.
Wu S, et al. Heparin sulfate is the attachment factor of duck Tembus virus on both BHK21 and DEF cells. Virol J. 2019;16(1):134.
Aliyu IA, et al. Annexin II as a dengue virus serotype 2 interacting protein mediating virus interaction on Vero cells. Viruses. 2019;11(4):335.
Kalia M, et al. Japanese encephalitis virus infects neuronal cells through a clathrin-independent endocytic mechanism. J Virol. 2013;87(1):148–62.
Acosta EG, Castilla V, Damonte EB. Functional entry of dengue virus into Aedes albopictus mosquito cells is dependent on clathrin-mediated endocytosis. J Gen Virol. 2008;89(Pt 2):474–84.
Sirohi D, et al. The 38 A resolution cryo-EM structure of Zika virus. Science. 2016;352(6284):467–70.
Roehrig JT, et al. Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion. Virology. 2013;441(2):114–25.
Fontes-Garfias CR, et al. Functional analysis of glycosylation of Zika virus envelope protein. Cell Rep. 2017;21(5):1180–90.
Mondotte JA, et al. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. J Virol. 2007;81(13):7136–48.
Wang P, et al. DC-SIGN as an attachment factor mediates Japanese encephalitis virus infection of human dendritic cells via interaction with a single high-mannose residue of viral E glycoprotein. Virology. 2016;488:108–19.
Hanna SL, et al. N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J Virol. 2005;79(21):13262–74.
Lin SR, et al. The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry. J Virol. 2011;85(10):5159–71.
Chen L, et al. Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. Antiviral Res. 2017;141:140–9.
Yang J, et al. Envelope protein mutations L107F and E138K are important for neurovirulence attenuation for Japanese encephalitis virus SA14-14-2 strain. Viruses. 2017;9(1):20.
Zhao Z, et al. Characterization of the E-138 (Glu/Lys) mutation in Japanese encephalitis virus by using a stable, full-length, infectious cDNA clone. J Gen Virol. 2005;86(Pt 8):2209–20.
Zheng X, et al. Acidity/alkalinity of Japanese encephalitis virus E protein residue 138 alters neurovirulence in mice. J Virol. 2018. https://doi.org/10.1128/JVI.00108-18.
Liu X, et al. The structure differences of Japanese encephalitis virus SA14 and SA14-14-2 E proteins elucidate the virulence attenuation mechanism. Protein Cell. 2019;10(2):149–53.
Lee E, Lobigs M. Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry. J Virol. 2000;74(19):8867–75.
Hurrelbrink RJ, McMinn PC. Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein. J Virol. 2001;75(16):7692–702.
Ryman KD, et al. Mutation in a 17D–204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology. 1998;244(1):59–65.
Huang YJ, et al. Mutagenesis analysis of T380R mutation in the envelope protein of yellow fever virus. Virol J. 2014;11:60.
Zhao D, et al. Identification of determinants that mediate binding between Tembusu virus and the cellular receptor heat shock protein A9. J Vet Sci. 2018;19(4):528–35.
Yang L, et al. Substantial attenuation of virulence of Tembusu virus strain PS is determined by an arginine at residue 304 of the envelope protein. J Virol. 2021;95(6):e02331-20.
Sun M, et al. Basic amino acid substitution at residue 367 of the envelope protein of Tembusu virus plays a critical role in pathogenesis. J Virol. 2020;94(8):e02011-19.
Liu H, et al. Structure-based mutational analysis of several sites in the E protein: implications for understanding the entry mechanism of Japanese encephalitis virus. J Virol. 2015;89(10):5668–86.
Watterson D, Kobe B, Young PR. Residues in domain III of the dengue virus envelope glycoprotein involved in cell-surface glycosaminoglycan binding. J Gen Virol. 2012;93(Pt 1):72–82.
Zhang F, Ren S, Zuo Y. DC-SIGN, DC-SIGNR and LSECtin: C-type lectins for infection. Int Rev Immunol. 2014;33(1):54–66.
Tassaneetrithep B, et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med. 2003;197(7):823–9.
Liu K, et al. mosGCTL-7, a C-Type Lectin Protein, Mediates Japanese Encephalitis Virus Infection in Mosquitoes. J Virol. 2017. https://doi.org/10.1128/JVI.01348-16.
Alen MM, et al. Crucial role of the N-glycans on the viral E-envelope glycoprotein in DC-SIGN-mediated dengue virus infection. Antiviral Res. 2012;96(3):280–7.
Routhu NK, et al. Glycosylation of Zika virus is important in host-virus interaction and pathogenic potential. Int J Mol Sci. 2019;20(20):5206.
Zhang S, et al. Chloroquine inhibits endosomal viral RNA release and autophagy-dependent viral replication and effectively prevents maternal to fetal transmission of Zika virus. Antiviral Res. 2019;169:104547.
Bos S, et al. The envelope residues E152/156/158 of Zika virus influence the early stages of virus infection in human cells. Cells. 2019;8(11):1444.
Scherwitzl I, Mongkolsapaja J, Screaton G. Recent advances in human flavivirus vaccines. Curr Opin Virol. 2017;23:95–101.
Sun L, et al. Adaptation and attenuation of duck Tembusu virus strain Du/CH/LSD/110128 following serial passage in chicken embryos. Clin Vaccine Immunol. 2014;21(8):1046–53.
Edelman R, et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis. 1994;170(6):1448–55.
Basset J, et al. A molecular determinant of west nile virus secretion and morphology as a target for viral attenuation. J Virol. 2020. https://doi.org/10.1128/JVI.00086-20.
Xin YY, et al. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg. 1988;39(2):214–7.
Hennessy S, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet. 1996;347(9015):1583–6.
Mueller DS, et al. Histidine protonation and the activation of viral fusion proteins. Biochem Soc Trans. 2008;36(Pt 1):43–5.
Fritz R, Stiasny K, Heinz FX. Identification of specific histidines as pH sensors in flavivirus membrane fusion. J Cell Biol. 2008;183(2):353–61.
Oliphant T, et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol. 2006;80(24):12149–59.
Nivarthi UK, et al. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. J Virol. 2017. https://doi.org/10.1128/JVI.02041-16.
McMinn PC, et al. Murray valley encephalitis virus envelope protein antigenic variants with altered hemagglutination properties and reduced neuroinvasiveness in mice. Virology. 1995;211(1):10–20.
Bressanelli S, et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 2004;23(4):728–38.
Liu Q, et al. Identification of heat shock protein A9 as a Tembusu virus binding protein on DF-1 cells. Virus Res. 2017;227:110–4.
Kanai R, et al. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol. 2006;80(22):11000–8.
Li C, et al. Inhibition of Japanese encephalitis virus entry into the cells by the envelope glycoprotein domain III (EDIII) and the loop3 peptide derived from EDIII. Antiviral Res. 2012;94(2):179–83.
Hung JJ, et al. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol. 2004;78(1):378–88.
van der Most RG, Corver J, Strauss JH. Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. Virology. 1999;265(1):83–95.
Lobigs M, et al. Host cell selection of Murray Valley encephalitis virus variants altered at an RGD sequence in the envelope protein and in mouse virulence. Virology. 1990;176(2):587–95.
Guerrero CA, et al. Integrin alpha(v)beta(3) mediates rotavirus cell entry. Proc Natl Acad Sci USA. 2000;97(26):14644–9.
Gavrilovskaya IN, et al. beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA. 1998;95(12):7074–9.
Lee JW, Chu JJ, Ng ML. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin. J Biol Chem. 2006;281(3):1352–60.
Hilgard P, Stockert R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology. 2000;32(5):1069–77.
Germi R, et al. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology. 2002;292(1):162–8.
Volk DE, et al. Structure of yellow fever virus envelope protein domain III. Virology. 2009;394(1):12–8.
Frei JC, et al. Engineered dengue virus domain III proteins elicit cross-neutralizing antibody responses in mice. J Virol. 2018. https://doi.org/10.1128/JVI.01023-18.
Chambers TJ, Nickells M. Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone. J Virol. 2001;75(22):10912–22.
Hahn CS, et al. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci USA. 1987;84(7):2019–23.
Nickells M, Chambers TJ. Neuroadapted yellow fever virus 17D: determinants in the envelope protein govern neuroinvasiveness for SCID mice. J Virol. 2003;77(22):12232–42.
Lee E, Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol. 2008;82(12):6024–33.
Hackett BA, Cherry S. Flavivirus internalization is regulated by a size-dependent endocytic pathway. Proc Natl Acad Sci USA. 2018;115(16):4246–51.
Fernandez-Garcia MD, et al. Vaccine and wild-type strains of yellow fever virus engage distinct entry mechanisms and differentially stimulate antiviral immune responses. mBio. 2016;7(1):e01956-15.
Hileman RE, et al. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. BioEssays. 1998;20(2):156–67.
Boigard H, et al. Zika virus-like particle (VLP) based vaccine. PLoS Negl Trop Dis. 2017;11(5):e0005608.
Khromykh AA, Varnavski AN, Westaway EG. Encapsidation of the flavivirus kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans. J Virol. 1998;72(7):5967–77.
Lu CY, et al. Single-round infectious particle antiviral screening assays for the Japanese encephalitis virus. Viruses. 2017;9(4):76.
de Wispelaere M, Yang PL. Mutagenesis of the DI/DIII linker in dengue virus envelope protein impairs viral particle assembly. J Virol. 2012;86(13):7072–83.
He Y, et al. Genetically stable reporter virus, subgenomic replicon and packaging system of duck Tembusu virus based on a reverse genetics system. Virology. 2019;533:86–92.
Kaufmann B, et al. Capturing a flavivirus pre-fusion intermediate. PLoS Pathog. 2009;5(11):e1000672.
Lv J, et al. The neutralizing antibody response elicited by Tembusu virus is affected dramatically by a single mutation in the stem region of the envelope protein. Front Microbiol. 2020;11:585194.
Khetarpal N, Khanna I. Dengue fever: causes, complications, and vaccine strategies. J Immunol Res. 2016;2016:6803098.
Rey FA, et al. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 2018;19(2):206–24.
Berneck BS, et al. A recombinant Zika virus envelope protein with mutations in the conserved fusion loop leads to reduced antibody cross-reactivity upon vaccination. Vaccines Basel. 2020;8(4):603.
Zhao H, et al. Structural basis of Zika virus-specific antibody protection. Cell. 2016;166(4):1016–27.
Zhao H, et al. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge. J Exp Med. 2020. https://doi.org/10.1084/jem.20191792.
Wu Y, et al. Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerg Microbes Infect. 2017;6(10):e89.
Oliphant T, et al. Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol. 2007;81(21):11828–39.
Dejnirattisai W, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16(2):170–7.
Barba-Spaeth G, et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536(7614):48–53.
Sapparapu G, et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016;540(7633):443–7.
Wang Q, et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci Transl Med. 2016;8(369):369ra179.
Cabral-Miranda G, et al. Zika virus-derived E-DIII protein displayed on immunologically optimized VLPs induces neutralizing antibodies without causing enhancement of dengue virus infection. Vaccines Basel. 2019;7(3):72.
Slon-Campos JL, et al. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. Nat Immunol. 2019;20(10):1291–8.
Hurtado-Monzon AM, et al. The role of anti-flavivirus humoral immune response in protection and pathogenesis. Rev Med Virol. 2020;30(4):e2100.
Navarro-Sanchez E, et al. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 2003;4(7):723–8.
Taguwa S, et al. Defining Hsp70 subnetworks in dengue virus replication reveals key vulnerability in flavivirus infection. Cell. 2015;163(5):1108–23.
Cabrera-Hernandez A, et al. Dengue virus entry into liver (HepG2) cells is independent of hsp90 and hsp70. J Med Virol. 2007;79(4):386–92.
Pujhari S, et al. Heat shock protein 70 (Hsp70) mediates Zika virus entry, replication, and egress from host cells. Emerg Microbes Infect. 2019;8(1):8–16.
Das S, et al. Heat shock protein 70 on Neuro2a cells is a putative receptor for Japanese encephalitis virus. Virology. 2009;385(1):47–57.
Nain M, et al. GRP78 is an important host factor for Japanese encephalitis virus entry and replication in mammalian cells. J Virol. 2017;91(6):7. https://doi.org/10.1128/JVI.02274-16.
Upanan S, Kuadkitkan A, Smith DR. Identification of dengue virus binding proteins using affinity chromatography. J Virol Methods. 2008;151(2):325–8.
Wang Y, Li Y, Ding T. Heat shock protein 90beta in the Vero cell membrane binds Japanese encephalitis virus. Int J Mol Med. 2017;40(2):474–82.
Hershkovitz O, et al. NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol. 2009;183(4):2610–21.
Zhu Z, et al. Zika virus targets glioblastoma stem cells through a SOX2-integrin alphavbeta5 axis. Cell Stem Cell. 2020;26(2):187-204e10.
Meertens L, et al. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe. 2012;12(4):544–57.
Niu J, et al. TIM-1 promotes Japanese encephalitis virus entry and infection. Viruses. 2018;10(11):630.
Carnec X, et al. The phosphatidylserine and phosphatidylethanolamine receptor CD300a binds dengue virus and enhances infection. J Virol. 2016;90(1):92–102.
Tan CW, et al. Cell surface alpha2,3-linked sialic acid facilitates Zika virus internalization. Emerg Microbes Infect. 2019;8(1):426–37.
Miller JL, et al. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 2008;4(2):17.
Sharma A, et al. Prohibitin 1/2 mediates Dengue-3 entry into human neuroblastoma (SH-SY5Y) and microglia (CHME-3) cells. J Biomed Sci. 2020;27(1):55.
Thepparit C, Smith DR. Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J Virol. 2004;78(22):12647–56.
Mukherjee S, et al. PLVAP and GKN3 are two critical host cell receptors which facilitate Japanese encephalitis virus entry into neurons. Sci Rep. 2018;8(1):11784.